Bolt halverar personalstyrkan när studieresultat försenas

Det amerikanska bioteknikbolaget Bolt Biotherapeutics genomför ännu en stor nedskärning. För andra gången på två år halveras personalstyrkan, i ett försök att frigöra resurser till bolagets pågående satsning på avancerad immunterapi.

By Ella Käck

October 3, 2025 10:45 AM

Bolt Biotherapeutics har det senaste året fokuserat på att utveckla läkemedelskandidaten BDC-4812, ett immunstimulerande antikroppskonjugat, som riktar sig mot proteinet Claudin 18.2. Detta protein är kopplat till vissa former av magsäckscancer och cancer i övergången mellan matstrupe och magsäck.

Under första halvåret 2026 hade Bolt planerat att presentera preliminära resultat från en fas I-studie med BDC-4812. Men så blir inte fallet.

1 month free trial

Get access to all content on Life Science Focus

No commitment or card information required

Try Life Science Focus now

Already a subscriber? Log In

Applies to personal subscription only.

{{ comments.count === 1 ? '1 comment' : comments.count > 1 ? '{0} comments'.replace('{0}', comments.count) : 'Write a comment' }}

By submitting the comment you accept the terms. See terms

Good comment behavior

Keep a good tone in your comments, avoid personal attacks and posts of marketing character. Apply only link on your comment if it is relevant to the debate.

Be aware that the debates are moderated by the portal's editorial team.

The comment has been created.

Your comment will not be visible until you activate it. In a few moments you will receive an email where you must click on a link to activate your comment.

Yes please, I would like to receive Life Science Focuss newsletter Read cookie and data policy.

Yes please, I would like to receive marketing, offers, surveys, etc. from Life Science Focus Read cookie and data policy.

{{ window.visitor.corporateClient.name }}

Corporate solution

{{ window.visitor.ipAccess.corporateClient.name }}

{{ window.visitor.corporateClient.name }}

Bolt halverar personalstyrkan när studieresultat försenas

Eli Lilly drops Alzheimer’s drug candidate after phase II trial

AstraZeneca unveils major cost-cutting drive

Sobi proposes Börje Ekholm as new chair

SynAct Pharma signs first dengue drug deal

Early gene therapy offers hope for some ALS patients

Lilly’s triple-G drug outperforms Ozempic in head-to-head trial

Rätt ventil för rätt applikation – hitta lösningen hos OEM Automatic

Structured Dialogue with SGS Fimko – a clearer path through MDR and IVDR

GRUBER aims to eliminate bottlenecks in pharmaceutical production

What if some of the most influential systems in healthcare are the least regulated?

From regulatory requirements to clinical reality: putting clinical & performance evidence into focus

AI in Medical Devices: Understanding the Review Process and Common Gaps

Upcoming Course: Quality Management System according to EN ISO 13485:2016 - in practice

Let's connect at COMPAMED 2026 in Düsseldorf

Smartare kvalitetskontroll med Zebra NS42 från OEM Automatic

Effektiv flödesmätning för vatten- och avloppssystem med FLUXUS WD

QAdvis & Scandinavian CRO are now Aurevia

Pumphuvudkonfiguration: Optimera flöde och vakuumprestanda